NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Intelligent Bio Solutions Inc. INBS
6 fiscal years on record · USD · FY2024 reported
SEC FILINGS ONLY
Revenue · FY2024
$3.1M
▼ 1.9% vs FY2023
EPS · FY24
$-2.00
Dividend / sh · FY24
—
Payout · FY24
—
ROE · FY24
-186.6%
Net margin · FY24
-346.2%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 3.1M
Revenue, FY2024 · full 6-year series below
Revenue
Net income
The company lost 346 cents on every revenue dollar this year.
Per share
USD -2.00
Diluted EPS, FY2024
EPS
The company pays no cash dividend.
Profitability
-186.6%
Return on equity, FY2024
ROE
Operating margin-348.7%
Net margin-346.2%
Return on assets-96.0%
Each USD of equity lost 187 cents this year.
Returned to shareholders
—
returned in FY2024 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+74.5% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+91.1%
+74.5%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.01B
Shares outstanding, FY2024
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 8.2M
total assets, end of FY2024
Total assetsUSD 8.2M
EquityUSD 3.0M
CashUSD 1.0M
Current ratio0.77×
Equity funds 36% of total assets.
History
6 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2024
2023
2022
2021
2020
2019
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
·
·
Income tax $B
·
·
·
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−2.00
−6.38
−127.00
−11.33
−0.68
−0.37
Dividend / sh $
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
ROE %
−186.6
−167.5
−204.0
−76.6
−142.6
·
Shares out B
0.01
0.00
0.00
0.01
0.01
0.01
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
21 of 21
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed